ArticleFrontiers in neurology2025
NGF/ERK signaling-mediated epigenetic regulation of neuropathic pain in the cerebrospinal fluid-contacting nucleus.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Full-Length Laminin-332 Promotes Integrin α3β1-Dependent Cutaneous Wound Closure in a Murine Model.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neuropathic pain (NP) is a debilitating condition that is associated with multiple molecular alterations in the nervous system. This is the first study to demonstrate the epigenetic regulatory function of nerve growth factor (NGF), mediated through the extracellular signal-regulated kinase (ERK) signaling pathway in the cerebrospinal fluid-contacting nucleus (CSF-CN), in relation to NP. The objective of this study was to characterize the role of NGF in this specific brain region and its downstream effects on histone acetylation in the chronic constriction injury (CCI) rat model. Methods: A rat model of NP was established using CCI. The study investigated the expression of NGF and its impact on pain pathways. NGF levels in the CSF-CN were assessed, and the effects of NGF on neuropathic pain were evaluated by administering NGF antibodies and ERK antagonists. Immunohistochemistry and Western blotting were used to measure key molecular markers, including p-ERK, THMA, and acetylated histone H3K56. Statistical analysis was performed, with significance set at a Results: CI induced significant upregulation of NGF in the CSF-CN. Treatment with NGF antibodies alleviated NP symptoms and reduced p-ERK levels in the CSF-CN. ERK antagonists further diminished thermal hyperalgesia and mechanical allodynia (THMA) and decreased the expression of acetylated histone H3K56. Conclusion: This is the first study to identify an NGF/ERK/ acetylated histone H3 (Ac-H3) signaling axis in the CSF-CN as a central mediator of neuropathic pain through epigenetic modulation. Our results suggest that targeting this novel signaling pathway may provide new therapeutic strategies for managing NP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.